FR2966698A1 - Composition, useful as dermocosmetic or antimicrobial composition for animal, comprises at least one psychotropic non-cannabinoid compound in solution in a solvent belonging to the family of glycol ethers - Google Patents
Composition, useful as dermocosmetic or antimicrobial composition for animal, comprises at least one psychotropic non-cannabinoid compound in solution in a solvent belonging to the family of glycol ethers Download PDFInfo
- Publication number
- FR2966698A1 FR2966698A1 FR1058941A FR1058941A FR2966698A1 FR 2966698 A1 FR2966698 A1 FR 2966698A1 FR 1058941 A FR1058941 A FR 1058941A FR 1058941 A FR1058941 A FR 1058941A FR 2966698 A1 FR2966698 A1 FR 2966698A1
- Authority
- FR
- France
- Prior art keywords
- composition
- psychotropic
- animal
- cannabinoid compound
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 19
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 13
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 13
- 230000000506 psychotropic effect Effects 0.000 title claims abstract description 13
- 150000001875 compounds Chemical class 0.000 title claims abstract description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 239000002904 solvent Substances 0.000 title claims abstract description 7
- -1 glycol ethers Chemical class 0.000 title claims abstract description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 title claims abstract description 5
- 241001465754 Metazoa Species 0.000 title claims description 20
- 239000004599 antimicrobial Substances 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 244000025254 Cannabis sativa Species 0.000 claims description 5
- OWSPBIWYEIHDKZ-OQLLNIDSSA-N 2-[(e)-6,7-dihydroxy-3,7-dimethyloct-2-enyl]-5-pentylbenzene-1,3-diol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC(O)C(C)(C)O)C(O)=C1 OWSPBIWYEIHDKZ-OQLLNIDSSA-N 0.000 claims description 4
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 4
- 229950011318 cannabidiol Drugs 0.000 claims description 4
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 4
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims description 4
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 claims description 4
- 229940065144 cannabinoids Drugs 0.000 claims description 4
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical group CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 239000000341 volatile oil Substances 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 241001299738 Malassezia pachydermatis Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000191980 Staphylococcus intermedius Species 0.000 description 7
- 239000000419 plant extract Substances 0.000 description 7
- 239000012085 test solution Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 240000004355 Borago officinalis Species 0.000 description 2
- 235000007689 Borago officinalis Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000555676 Malassezia Species 0.000 description 2
- 244000235659 Rubus idaeus Species 0.000 description 2
- 235000009122 Rubus idaeus Nutrition 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001010481 Staphylococcus intermedius NCTC 11048 Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/08—Oxygen or sulfur directly attached to an aromatic ring system
- A01N31/16—Oxygen or sulfur directly attached to an aromatic ring system with two or more oxygen or sulfur atoms directly attached to the same aromatic ring system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N49/00—Biocides, pest repellants or attractants, or plant growth regulators, containing compounds containing the group, wherein m+n>=1, both X together may also mean —Y— or a direct carbon-to-carbon bond, and the carbon atoms marked with an asterisk are not part of any ring system other than that which may be formed by the atoms X, the carbon atoms in square brackets being part of any acyclic or cyclic structure, or the group, wherein A means a carbon atom or Y, n>=0, and not more than one of these carbon atoms being a member of the same ring system, e.g. juvenile insect hormones or mimics thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Environmental Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Pest Control & Pesticides (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Insects & Arthropods (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
La présente invention s'inscrit dans le domaine du traitement antimicrobien des animaux. Plus particulièrement, elle concerne une composition dermo-cosmétique anti-microbienne pour animaux, destinée à une application par voie topique. The present invention is in the field of antimicrobial treatment of animals. More particularly, it relates to an antimicrobial dermo-cosmetic composition for animals, intended for topical application.
On entend dans la présente description, par le terme anti-microbien, la capacité à éliminer les micro-organismes, notamment les bactéries et les champignons. Le terme animaux est en outre entendu dans la présente description comme exclusif des être humains. The term "anti-microbial" in the present description means the ability to eliminate microorganisms, especially bacteria and fungi. The term animals is further understood in the present description as exclusive to humans.
On connait de l'art antérieur de nombreuses compositions antimicrobiennes topiques pour animaux. Ces compositions, qui mettent en oeuvre des composés à propriétés anti-microbiennes divers, se présentent généralement sous forme de crèmes, de shampoings ou de lotions. Pour être efficaces, elles doivent être appliquées fréquemment, et sur toute la surface cutanée de l'animal, ce qui s'avère parfois compliqué pour la personne qui doit traiter l'animal, et qui peut être désagréable pour ce dernier et le perturber. La présente invention vise à proposer une composition antimicrobienne pour animaux, qui permette de traiter ceux-ci efficacement tout en facilitant les opérations de traitement et en les rendant plus confortables tant pour l'utilisateur que pour l'animal. A cet effet, il est proposé selon l'invention une composition dermocosmétique anti-microbienne pour animaux, pour application par voie topique, qui comporte, en tant que principe actif, au moins un composé cannabinoïde non-psychotrope en solution dans un solvant appartenant à la famille des éthers de glycol. Préférentiellement, le solvant est l'éthoxydiglycol, également appelé di(éthylène glycol) éthyl éther. La composition selon l'invention tire ainsi avantageusement profit d'une part des propriétés anti-microbiennes des cannabinoïdes non- psychotropes, et d'autre part des propriétés des éthers de glycol, qui sont des solvants aptes à constituer un vecteur de diffusion des principes actifs de la composition sur la surface cutanée, puis à induire le stockage de ces principes actifs dans les glandes sébacées et leur relargage progressif, depuis ces glandes sébacées, sur la surface cutanée, par l'intermédiaire du sébum qu'elles produisent naturellement. Il a été découvert par les présents inventeurs que la combinaison d'un composé cannabinoïde non-psychotrope et de I'éthoxydiglycol permettait de traiter efficacement et intégralement l'animal, par une seule application réalisée sur une zone réduite de sa surface cutanée une fois par semaine seulement. Many prior art antimicrobial compositions for animals are known from the prior art. These compositions, which use compounds with various anti-microbial properties, are generally in the form of creams, shampoos or lotions. To be effective, they must be applied frequently, and over the entire skin surface of the animal, which is sometimes complicated for the person who must treat the animal, and which can be unpleasant for the animal and disrupt it. The present invention aims to provide an antimicrobial composition for animals, which allows to treat them effectively while facilitating the treatment operations and making them more comfortable for both the user and the animal. For this purpose, it is proposed according to the invention an antimicrobial dermocosmetic composition for animals, for topical application, which comprises, as active principle, at least one non-psychotropic cannabinoid compound in solution in a solvent belonging to the family of glycol ethers. Preferably, the solvent is ethoxydiglycol, also called di (ethylene glycol) ethyl ether. The composition according to the invention thus advantageously benefits, on the one hand, from the anti-microbial properties of non-psychotropic cannabinoids and, on the other hand, from the properties of glycol ethers, which are solvents capable of constituting a vector for the diffusion of the principles. active ingredients of the composition on the skin surface, then to induce the storage of these active principles in the sebaceous glands and their gradual release from these sebaceous glands on the skin surface, through the sebum they produce naturally. It has been discovered by the present inventors that the combination of a non-psychotropic cannabinoid compound and ethoxydiglycol enables the animal to be treated effectively and integrally by a single application carried out on a reduced area of its cutaneous surface once per week. week only.
Le traitement s'entend ici principalement d'un traitement préventif, visant notamment à éviter les récidives d'infections microbiennes cutanées chez l'animal. Dans des modes de réalisation préférés de l'invention, la composition comporte au moins un composé cannabinoïde non-psychotrope choisi parmi le cannabidiol, le cannabigérol et le carmagérol, ou un mélange de ces composés. Préférentiellement, la quantité totale de cannabinoïdes non-psychotropes est comprise entre 2 et 25 % du poids total de la composition. Selon une caractéristique avantageuse de l'invention, la composition comporte un extrait de capitules de la plante Cannabis sativa contenant le ou les composé(s) cannabinoïde(s) non-psychotrope(s). Les extraits obtenus par extraction par l'acétone à partir d'une poudre de capitules de la plante sont notamment particulièrement préférés dans le cadre de l'invention. De préférence, l'extrait de la plante comporte de 35 à 45 % en poids 25 de cannabigérol, de 3 à 10 % en poids de cannabidiol et de 0,2 à 2 % en poids de carmagérol. Dans des modes de réalisation préférés de l'invention, la composition comporte en outre un mélange d'huiles essentielles à propriétés antimicrobiennes. 30 La composition peut également comporter divers constituants à propriétés anti-inflammatoires, tels que l'huile de Borago officinalis, et/ou à propriétés d'hydratation et nourrissantes de la surface cutanée, tels que les constituants riches en acides gras polyinsaturés, par exemple l'huile de Rubus idaeus. L'invention concerne également un procédé d'utilisation de la composition répondant à l'une ou plusieurs des caractéristiques ci-avant, qui comprend l'application de la composition sur une zone réduite de la surface cutanée de l'animal une fois par semaine. La dose appliquée est fonction du poids de l'animal, et aisément déterminable par l'homme du métier. L'invention sera maintenant plus précisément décrite dans le cadre des exemples ci-après, qui n'en sont nullement limitatifs. Exemple 1 - Production d'un extrait de la plante Cannabis sativa Un extrait de la variété CARMA de la plante Cannabis sativa est obtenu conformément à l'enseignement de la demande de brevet WO 2009/043836, par broyage de capitules de la plante, chauffage de la poudre sèche obtenue à 120 °C pendant 2 heures, et trois extractions successives par l'acétone. Après réunion des fractions d'extraction et évaporation de l'acétone, on obtient un extrait sec qui comporte principalement du cannabigérol, pour 35-45 % en poids, du cannabidiol, pour 3-10 % en poids et du carmagérol, pour 0,2-2 % en poids. Exemple 2 - Analyse des propriétés anti-microbiennes de l'extrait de la plante Cannabis sativa La Concentration Minimale Inhibitrice (CMI) et la Concentration Minimale Bactéricide (CMB) de l'extrait sec obtenu conformément à l'Exemple 1 sont déterminées pour deux germes que sont le germe bactérien Staphylococcus intermedius et le germe fongique Malassezia pachydermatis. 1 g de l'extrait végétal sec de l'Exemple 1 sont dissous dans 99 ml de DMSO (sulfoxyde diméthylique). La solution est diluée au 1/100è" dans un bouillon de Mueller Hinton. The treatment here refers primarily to a preventive treatment, aimed in particular to prevent recurrence of skin microbial infections in animals. In preferred embodiments of the invention, the composition comprises at least one non-psychotropic cannabinoid compound selected from cannabidiol, cannabigerol and carmagerol, or a mixture of these compounds. Preferably, the total amount of non-psychotropic cannabinoids is between 2 and 25% of the total weight of the composition. According to an advantageous characteristic of the invention, the composition comprises an extract of flower heads of the plant Cannabis sativa containing the compound (s) cannabinoid (s) non-psychotropic (s). Extracts obtained by extraction with acetone from a plant head powder are particularly particularly preferred in the context of the invention. Preferably, the plant extract comprises from 35 to 45% by weight of cannabigerol, from 3 to 10% by weight of cannabidiol and from 0.2 to 2% by weight of carmagerol. In preferred embodiments of the invention, the composition further comprises a mixture of essential oils with antimicrobial properties. The composition may also comprise various constituents with anti-inflammatory properties, such as Borago officinalis oil, and / or with moisturizing properties and nourishing the cutaneous surface, such as constituents rich in polyunsaturated fatty acids, for example the oil of Rubus idaeus. The invention also relates to a method of using the composition corresponding to one or more of the above features, which comprises applying the composition to a reduced area of the cutaneous surface of the animal once a week. . The dose applied is a function of the weight of the animal, and easily determinable by those skilled in the art. The invention will now be more specifically described in the context of the following examples, which are in no way limiting. EXAMPLE 1 Production of an Extract of the Plant Cannabis sativa An extract of the CARMA variety of the plant Cannabis sativa is obtained in accordance with the teaching of the patent application WO 2009/043836, by crushing the flower heads of the plant, heating dry powder obtained at 120 ° C for 2 hours, and three successive extractions with acetone. After combining the extraction fractions and evaporation of the acetone, a dry extract is obtained which mainly comprises cannabigerol, for 35-45% by weight, cannabidiol, for 3-10% by weight and carmagerol, for 0, 2-2% by weight. EXAMPLE 2 Analysis of the Anti-microbial Properties of the Plant Extract Cannabis sativa The Minimal Inhibitory Concentration (MIC) and the Minimal Bactericidal Concentration (CMB) of the dry extract obtained according to Example 1 are determined for two seeds which are the bacterial germ Staphylococcus intermedius and the fungal germ Malassezia pachydermatis. 1 g of the dry vegetable extract of Example 1 are dissolved in 99 ml of DMSO (dimethyl sulfoxide). The solution is diluted 1: 100 in Mueller Hinton broth.
Cette solution mère est utilisée pour obtenir, par dilution dans du bouillon de Mueller Hinton, des solutions tests aux concentrations suivantes en extrait végétal : 100, 80, 50, 30, 20, 10, 5, 2 et 1 µg/ml pour Staphylococcus intermedius 100, 80, 60, 50, 40, 30, 20, 10, 5 et 1 µg/ml pour Malassezia pachydermatis Pour chacune des solutions tests ci-dessus, un volume de 100 µl de Staphylococcus intermedius DSM 20373 à 10' UFC/ml, ou un volume de 100 µl de Malassezia pachydermatis DSM 6172 à 106 UFC/ml (où UFC/ml signifie Unité Formant Colonie par millilitre), est inoculé dans 10 ml de solution. Deux solutions témoins dites positives contenant du DMSO à 1 % en 10 volume dans du bouillon de Mueller Hinton sont ensemencées avec les germes testés, aux concentrations ci-dessus. Deux solutions témoins dites négatives sont constituées par la solution mère seule. Les solutions tests et les solutions témoins ci-dessus sont incubées, 15 en tubes à essais, 24h à 35 °C pour Staphylococcus intermedius et 48 h à 25 °C pour Malassezia pachydermatis. On observe visuellement dans les solutions témoins positives la présence d'une culture de germes tant pour Staphylococcus intermedius que pour Malassezia pachydermatis. 20 Les solutions témoins négatives ne présentent aucune croissance bactérienne ou fongique. Pour les solutions tests, on obtient les résultats présentés dans le Tableau 1 ci-après. Concentration 100 80 60 50 40 30 20 10 5 2 1 (µg/ml) Staphylococcus - - l - l - - + + + + intermedius Malassezia - - - - - - + + + / + pachydermatis Tableau 1 - Culture des germes dans les solutions tests en tubes à essais où + exprime la présence de culture observée à l'ceil nu - exprime l'absence de culture observée à l'ceil nu On détermine à partir des résultats ci-avant la CMI de l'extrait végétal, qui est associée à la plus petite concentration donnant lieu à une absence de culture visible à I'ceil nu. Pour le germe bactérien Staphylococcus intermedius, la CMI est située entre 10 et 20 µg/ml. Pour le germe fongique Malassezia pachydermatis, la CMI est située entre 20 et 30 µg/ml. Les solutions tests de concentrations 80, 50, 30 et 20 µg/ml pour Staphylococcus intermedius, et de concentrations 60, 50, 40 et 30 µg/ml pour Malassezia pachydermatis, sont mises en culture sur gélose respectivement à 35 °C pendant 24 heures et 25 °C pendant 48 heures, après l'étape d'incubation précédente. On obtient les résultats présentés dans le Tableau 2 ci-après. Concentration 80 60 50 40 30 20 (µg/ml) Staphylococcus - l - l - + intermedius Malassezia l - - - + l pachydermatis Tableau 2 - Culture des germes dans les solutions tests sur gélose où + exprime la présence de culture - exprime l'absence de culture On détermine à partir des résultats ci-avant la CMB de l'extrait végétal, qui est associée à la plus petite concentration donnant lieu à une absence de culture sur gélose (correspondant à 99,9 % des germes détruits). This stock solution is used to obtain, by dilution in Mueller Hinton broth, test solutions with the following concentrations of plant extracts: 100, 80, 50, 30, 20, 10, 5, 2 and 1 μg / ml for Staphylococcus intermedius 100, 80, 60, 50, 40, 30, 20, 10, 5 and 1 μg / ml for Malassezia pachydermatis For each of the test solutions above, a volume of 100 μl of Staphylococcus intermedius DSM 20373 at 10 CFU / ml or a volume of 100 μl of Malassezia pachydermatis DSM 6172 at 106 CFU / ml (where CFU / ml means Colony Forming Unit per milliliter) is inoculated into 10 ml of solution. Two so-called positive control solutions containing 1% by volume DMSO in Mueller Hinton Broth are seeded with the tested organisms at the above concentrations. Two so-called negative control solutions consist of the mother solution alone. The test solutions and the above control solutions are incubated in test tubes 24h at 35 ° C. for Staphylococcus intermedius and 48 hours at 25 ° C. for Malassezia pachydermatis. The presence of a seed culture for both Staphylococcus intermedius and Malassezia pachydermatis is visually observed in the positive control solutions. Negative control solutions show no bacterial or fungal growth. For the test solutions, the results presented in Table 1 below are obtained. Concentration 100 80 60 50 40 30 20 10 5 2 1 (μg / ml) Staphylococcus - - l - - - + + + + intermediates Malassezia - - - - - - + + + / + pachydermatis Table 1 - Culture of germs in test solutions in test tubes where + expresses the presence of culture observed on the naked eye - expresses the absence of culture observed in the naked eye The MIC results from the above results of the plant extract, which is associated with the lowest concentration giving rise to an absence of culture visible to the naked eye. For the bacterial germ Staphylococcus intermedius, the MIC is between 10 and 20 μg / ml. For the fungal germ Malassezia pachydermatis, the MIC is between 20 and 30 μg / ml. The test solutions of concentrations 80, 50, 30 and 20 μg / ml for Staphylococcus intermedius, and concentrations of 60, 50, 40 and 30 μg / ml for Malassezia pachydermatis, are cultured on agar respectively at 35 ° C. for 24 hours. and 25 ° C for 48 hours after the previous incubation step. The results presented in Table 2 below are obtained. Concentration 80 60 50 40 30 20 (μg / ml) Staphylococcus - l - l - + Intermediates Malassezia l - - - + l pachydermatis Table 2 - Culture of germs in test solutions on agar where + expresses the presence of culture - expresses absence of culture The results obtained from the above results from the CMB of the plant extract, which is associated with the lowest concentration giving rise to an absence of agar culture (corresponding to 99.9% of the destroyed seeds).
Pour le germe bactérien Staphylococcus intermedius, la CMB est située entre 20 et 30 µg/ml. For the bacterial germ Staphylococcus intermedius, the CMB is between 20 and 30 μg / ml.
Pour le germe fongique Malassezia pachydermatis, la CMB est située entre 30 et 40 gg/ml. Les résultats ci-avant démontrent l'efficacité anti-microbienne de l'extrait végétal contenant les cannabinoïdes non-psychotropes sur les germes testés, tant bactériens que fongiques, et ce à de faibles concentrations. For the fungal germ Malassezia pachydermatis, the CMB is between 30 and 40 gg / ml. The results above demonstrate the anti-microbial efficacy of the plant extract containing the non-psychotropic cannabinoids on the tested bacteria, both bacterial and fungal, and at low concentrations.
Exemple 3 - Composition anti-microbienne Une composition anti-microbienne pour application par voie topique comprend l'extrait végétal de l'Exemple 1, et les constituants suivants, dans les proportions en poids ci-après : Huile de Rubus idaeus 10 0/0 Huile de Borago officinalis 6 0/0 Mélange d'huiles essentielles anti-microbiennes : 4 0/0 Extrait végétal de l'Exemple 1 0,2 0/0 Ethoxydiglycol qsp 100 0/0 A titre d'exemple, cette composition est appliquée par voie topique sur une ou plusieurs zones réduites, de quelques cm2, par exemple de 2 cm2, de la surface cutanée de l'animal, selon la posologie suivante : 0,6 ml / semaine pour chien ou chat de 0 à 10 kg, 1,2 ml / semaine pour chien de 10 à 20 kg, 2,4 ml / semaine pour chien de 20 à 40 kg, à raison d'une application par semaine. Un tel mode d'administration, pendant une durée de deux mois environ, permet de prévenir efficacement l'apparition de toute infection microbienne cutanée chez l'animal. Example 3 - Anti-microbial composition An antimicrobial composition for topical application comprises the plant extract of Example 1, and the following constituents, in the following proportions by weight: Rubus idaeus oil 10% Borago officinalis oil 6 0/0 Anti-microbial essential oil mixture: 4 0/0 Vegetable extract of Example 1 0.2 0/0 Ethoxydiglycol qs 100 0/0 By way of example, this composition is applied topically on one or more reduced areas, a few cm2, for example 2 cm2, of the cutaneous surface of the animal, according to the following dosage: 0.6 ml / week for dog or cat from 0 to 10 kg, 1.2 ml / week for dogs from 10 to 20 kg, 2.4 ml / week for dogs from 20 to 40 kg, one application per week. Such a mode of administration, for a period of about two months, effectively prevents the appearance of any microbial skin infection in the animal.
La description ci-avant illustre clairement que par ses différentes caractéristiques et leurs avantages, la présente invention atteint les objectifs qu'elle s'était fixés. En particulier, elle fournit une composition anti-microbienne qui permet de prévenir efficacement les infections microbiennes cutanées chez 6 l'animal, au moyen d'un nombre limité d'applications, qui plus est réalisées sur des zones réduites de sa surface cutanée. Un tel traitement est peu contraignant à mettre en oeuvre, et il n'induit aucun stress pour l'animal. The above description clearly illustrates that by its different characteristics and advantages, the present invention achieves the objectives it has set for itself. In particular, it provides an antimicrobial composition which effectively prevents skin microbial infections in the animal, by means of a limited number of applications, which moreover is carried out on reduced areas of its skin surface. Such a treatment is not very restrictive to implement, and it induces no stress for the animal.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1058941A FR2966698B1 (en) | 2010-10-29 | 2010-10-29 | ANTI-MICROBIAL DERMO-COSMETIC COMPOSITION FOR ANIMALS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1058941A FR2966698B1 (en) | 2010-10-29 | 2010-10-29 | ANTI-MICROBIAL DERMO-COSMETIC COMPOSITION FOR ANIMALS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2966698A1 true FR2966698A1 (en) | 2012-05-04 |
| FR2966698B1 FR2966698B1 (en) | 2013-04-26 |
Family
ID=43534235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1058941A Active FR2966698B1 (en) | 2010-10-29 | 2010-10-29 | ANTI-MICROBIAL DERMO-COSMETIC COMPOSITION FOR ANIMALS |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2966698B1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020252522A1 (en) * | 2019-06-18 | 2020-12-24 | Botanix Pharmaceuticals Limited | Antibacterial dosage regime using cannabinoids |
| EP3258942B1 (en) * | 2015-02-16 | 2021-01-13 | APIRX Pharmaceutical USA, LLC | Cosmetic and topical compositions comprising cannabigerol and cannabidiol |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| US11084770B2 (en) | 2016-12-07 | 2021-08-10 | Treehouse Biotech, Inc. | Cannabis extracts |
| US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1374903A1 (en) * | 2002-06-26 | 2004-01-02 | Innovet Italia S.r.l. | Pharmaceutical composition for the prevention of the development and progression of mycotic skin surface diseases |
| FR2860434A1 (en) * | 2003-10-06 | 2005-04-08 | Dermo Cosmetique Animale L D C | DERMO COSMETIC COMPOSITION FOR PETS. |
| US20090042974A1 (en) * | 2007-08-07 | 2009-02-12 | Anson David Parker | Compositions And Methods Relating To Extensible Transgenic Vector Assembler, Pestilence Ridder, Plus Cannabinoid Producer |
-
2010
- 2010-10-29 FR FR1058941A patent/FR2966698B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1374903A1 (en) * | 2002-06-26 | 2004-01-02 | Innovet Italia S.r.l. | Pharmaceutical composition for the prevention of the development and progression of mycotic skin surface diseases |
| FR2860434A1 (en) * | 2003-10-06 | 2005-04-08 | Dermo Cosmetique Animale L D C | DERMO COSMETIC COMPOSITION FOR PETS. |
| US20090042974A1 (en) * | 2007-08-07 | 2009-02-12 | Anson David Parker | Compositions And Methods Relating To Extensible Transgenic Vector Assembler, Pestilence Ridder, Plus Cannabinoid Producer |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3258942B1 (en) * | 2015-02-16 | 2021-01-13 | APIRX Pharmaceutical USA, LLC | Cosmetic and topical compositions comprising cannabigerol and cannabidiol |
| US11084770B2 (en) | 2016-12-07 | 2021-08-10 | Treehouse Biotech, Inc. | Cannabis extracts |
| US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| WO2020252522A1 (en) * | 2019-06-18 | 2020-12-24 | Botanix Pharmaceuticals Limited | Antibacterial dosage regime using cannabinoids |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2966698B1 (en) | 2013-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10575521B2 (en) | Antimicrobial, antibacterial and spore germination inhibiting activity from an avocado extract enriched in bioactive compounds | |
| JP3739803B2 (en) | Novel antimicrobial cosmetic composition | |
| FR2966698A1 (en) | Composition, useful as dermocosmetic or antimicrobial composition for animal, comprises at least one psychotropic non-cannabinoid compound in solution in a solvent belonging to the family of glycol ethers | |
| KR101161479B1 (en) | Pharmaceutical composition comprising chaff vinegar for preventing or treating inflammatory disease | |
| Purgato et al. | Salvinia auriculata: chemical profile and biological activity against Staphylococcus aureus isolated from bovine mastitis | |
| CA2878496A1 (en) | Use of a myrtle extract as an anti-biofilm agent against p. acnes | |
| US20130337095A1 (en) | Antimicrobial composition and its method of use | |
| EP3193936A1 (en) | Potentiated antimicrobial agents | |
| KR101433823B1 (en) | External Composition for Skin Using an Extract or a Fraction of Padina arborescens | |
| US20100111994A1 (en) | Anti-bacterial composition and method of using same | |
| EP2583662B1 (en) | Composition comprising a meroterpen to manage oily skin with tendency to develop acne | |
| KR102009604B1 (en) | Antimicrobial composition comprising lonicera japonica extract and magnolia obovata extract | |
| Ragab et al. | Antimicrobial effects of essential oils of Artemisia annua, Mentha longifolia, and Vitex agnus-castus and their nanoemulsions against pathogenic microbes causing cattle mastitis | |
| JP2021042163A (en) | Uses of extract of primulaceae | |
| Stratev et al. | coggigria Scop.) against Aeromonas hydro-phila (ATCC 7965) | |
| Kwetché et al. | Antibacterial Potential of Hydro-Ethanolic Extracts from Syzygium Aromaticum (Myrtaceae) on Periodontal Bacteria | |
| EP3429579B1 (en) | Enhanced tulathromycin | |
| KR20120086123A (en) | External Composition for Skin Having Antibacterial Activities | |
| WO2020193742A1 (en) | Use of dianhydrohexitol to eliminate the cosmetic effects of acne, dandruff and bad odors | |
| KR102126408B1 (en) | Antibiotic composition containing extract of Syzygii Flos and extract of Magnoliae Cortex | |
| FR3056403A1 (en) | ANTIMICROBIAL ACTIVITY OF A TERPENIC MIXTURE OF VEGETABLE ORIGIN | |
| FR3094218A1 (en) | Using dianhydrohexitol to remove cosmetic effects of dandruff | |
| WO2020193744A1 (en) | Use of dianhydrohexitol for preserving cosmetic preparations | |
| FR3094216A1 (en) | Use of dianhydrohexitol to eliminate the cosmetic effects of bad odors | |
| FR3064179A1 (en) | CONSERVATIVE AGENT CONTAINING HINOKITIOL WITH AT LEAST ONE ACID AND COMPOSITIONS PRESERVED THEREBY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 6 |
|
| PLFP | Fee payment |
Year of fee payment: 7 |
|
| PLFP | Fee payment |
Year of fee payment: 8 |
|
| PLFP | Fee payment |
Year of fee payment: 9 |
|
| PLFP | Fee payment |
Year of fee payment: 10 |
|
| PLFP | Fee payment |
Year of fee payment: 11 |
|
| PLFP | Fee payment |
Year of fee payment: 12 |
|
| PLFP | Fee payment |
Year of fee payment: 13 |
|
| PLFP | Fee payment |
Year of fee payment: 14 |